DEKK-TEC, INC.

Address

725 TOPAZ STREET
NEW ORLEANS, LA, 70124-

Information

DUNS: 139242184
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. A Phase I Clinical Trial: Binary Therapy with DM-CHOC-PEN and WBRT in Adults with Cancer Involving the CNS

    Amount: $143,294.00

    The goal of this Phase I clinical trial will be to document safety and potential usefulness of demethyl cholesteryloxycarbonylpenclomedine DM CHOC PEN in combination with de escalating doses of ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. The DEKK-TEC I-Corp Team

    Amount: $230,724.00

    DESCRIPTION provided by applicant The primary goal of this Phase I pediatric oncology clinical trial will be to evaluate the safety and use of demethyl cholesteryloxycarbonylpenclomedine DM CH ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  3. 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica

    Amount: $1,161,453.00

    DESCRIPTION (provided by applicant): The principal goal of this research project will be to evaluate 4-demethyl-4- cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a polychlorinated cholesterol carbo ...

    SBIRPhase II2013Department of Health and Human Services
  4. Camptothecin Analogs for Cancer Therapy

    Amount: $837,217.00

    DESCRIPTION (provided by applicant): 7-Butyl-10-aminocamptothecin (BACPT), as a water-soluble dipeptide pro-drug - BACPTDP, is a novel camptothecin analog that has increased activity in hypoxic/acidic ...

    SBIRPhase II2010Department of Health and Human Services
  5. 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr

    Amount: $272,657.00

    DESCRIPTION (provided by applicant): The object of the proposed research is to conduct a Phase 1 clinical trial with 4-demethyl-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a carbonate derivative ...

    SBIRPhase I2008Department of Health and Human Services
  6. Camptothecin Analogs for Cancer Therapy

    Amount: $158,895.00

    DESCRIPTION (provided by applicant): 7-butyl-10-aminocamptothecin (BACPT) and its water-soluble dipeptide pro-drug, are novel camptothecins that were designed to be used in the treatment of childhood ...

    SBIRPhase I2007Department of Health and Human Services
  7. SBIR TOPIC 232 MANUFACTURE OF 4-DEMETHYL 4-CHOLESTEROLYL-PENCLOMEDINE

    Amount: $150,000.00

    N/A

    SBIRPhase I2007Department of Health and Human Services
  8. Clinical Development of 4-Hydroperoxyifosfamide

    Amount: $539,124.00

    DESCRIPTION (provided by applicant): 4-Hydroperoxyifosfamide (HOO-IFOS) is a stable, pre-activated form (peroxide) of 4-HO-IFOS, the initial metabolite of Ifosfamide (IFOS). Under physiological condit ...

    SBIRPhase II2006Department of Health and Human Services
  9. A-007: Immune Modulation of HPV- Associated Neoplasia

    Amount: $2,300,490.00

    DESCRIPTION (provided by applicant): 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) was originally developed as an immune modulator of immune deficiency associated cancerous growths. In ...

    SBIRPhase II2005Department of Health and Human Services
  10. CLINICAL DEVELOPMENT OF 4-HYDROPEROXYIFOSFAMIDE

    Amount: $185,641.00

    DESCRIPTION (provided by applicant): The objective of the proposed research is to synthesize 4-hydroperoxyifosfamide (HOO-IFOS) in sufficient quantity for evaluation in vivo against a human osteosarc ...

    SBIRPhase I2002Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government